Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

C. Qian, C.-J. Lai, R. Bao, D.-G. Wang, J. Wang, G.-X. Xu, R. Atoyan, H. Qu, L. Yin, M. Samson, B. Zifcak, A. W. S. Ma (+5 others)
2012 Clinical Cancer Research  
Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting signaling networks and act synergistically with phosphatidylinositol 3-kinase (PI3K) inhibitors, we developed a strategy to simultaneously inhibit HDACs and PI3K in cancer cells. Experimental Design: We constructed dual-acting inhibitors by incorporating HDAC inhibitory functionality into a PI3K inhibitor pharmacophore. CUDC-907, a development candidate selected from these
more » ... lected from these dual inhibitors, was evaluated in vitro and in vivo to determine its pharmacologic properties, anticancer activity, and mechanism of action. Results: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes. Through its integrated HDAC inhibitory activity, CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling molecules such as RAF, MEK, MAPK, and STAT-3, as well as upstream receptor tyrosine kinases. CUDC-907 shows greater growth inhibition and proapoptotic activity than single-target PI3K or HDAC inhibitors in both cultured and implanted cancer cells. Conclusions: CUDC-907 may offer improved therapeutic benefits through simultaneous, sustained disruption of multiple oncogenic signaling networks. Clin Cancer Res; 18(15); 4104-13. Ó2012 AACR. Materials and Methods Reagents CUDC-907, vorinostat [suberoylanilide hydroxamic acid (SAHA)], panobinostat (LBH-589), GDC-0941, and BEZ-235 were synthesized in-house. CAL-101 was purchased from Active Biochem (Maplewood, NJ). For in vitro assays, compounds were dissolved in dimethyl sulfoxide (DMSO) as stock and stored at À80 C. For in vivo studies, CUDC-907 was formulated in 30% Captisol (Cydex Pharmaceuticals, Inc.).
doi:10.1158/1078-0432.ccr-12-0055 pmid:22693356 fatcat:lzjo4hygsff6xcvgdj6izxmn34